145 related articles for article (PubMed ID: 33536266)
1. Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2.
Campbell KS
Cancer Immunol Res; 2021 Feb; 9(2):128. PubMed ID: 33536266
[TBL] [Abstract][Full Text] [Related]
2. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.
Bhatt RS; Berjis A; Konge JC; Mahoney KM; Klee AN; Freeman SS; Chen CH; Jegede OA; Catalano PJ; Pignon JC; Sticco-Ivins M; Zhu B; Hua P; Soden J; Zhu J; McDermott DF; Arulanandam AR; Signoretti S; Freeman GJ
Cancer Immunol Res; 2021 Feb; 9(2):156-169. PubMed ID: 33229411
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells.
Palmer WH; Leaton LA; Campos Codo A; Crute B; Roest J; Zhu S; Petersen J; Tobin RP; Hume PS; Stone M; van Bokhoven A; Gerich ME; McCarter MD; Zhu Y; Janssen WJ; Vivian JP; Trowsdale J; Getahun A; Rossjohn J; Cambier J; Loh L; Norman PJ
Sci Immunol; 2023 Jun; 8(84):eade5343. PubMed ID: 37390222
[TBL] [Abstract][Full Text] [Related]
4. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target.
Wei Y; Ren X; Galbo PM; Moerdler S; Wang H; Sica RA; Etemad-Gilbertson B; Shi L; Zhu L; Tang X; Lin Q; Peng M; Guan F; Zheng D; Chinai JM; Zang X
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34244312
[TBL] [Abstract][Full Text] [Related]
5. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.
Li Y; Lv C; Yu Y; Wu B; Zhang Y; Lang Q; Liang Z; Zhong C; Shi Y; Han S; Xu F; Tian Y
J Adv Res; 2023 May; 47():137-150. PubMed ID: 35933091
[TBL] [Abstract][Full Text] [Related]
6. HHLA2 immune-regulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
[TBL] [Abstract][Full Text] [Related]
7. Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model.
Ren X; Corrigan DT; Zang X
STAR Protoc; 2022 Dec; 3(4):101818. PubMed ID: 36386885
[TBL] [Abstract][Full Text] [Related]
8. Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans.
Du Z; Gjertson DW; Reed EF; Rajalingam R
Immunogenetics; 2007 Jan; 59(1):1-15. PubMed ID: 17103212
[TBL] [Abstract][Full Text] [Related]
9. Compound KIR-HLA genotype analyses in the Iranian population by a novel PCR-SSP assay.
Tajik N; Shahsavar F; Nasiri M; Radjabzadeh MF
Int J Immunogenet; 2010 Jun; 37(3):159-68. PubMed ID: 20193031
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory Killer Immunoglobulin-like Receptors to self HLA-B and HLA-C ligands contribute differentially to Natural Killer cell functional potential in HIV infected slow progressors.
Kamya P; Tallon B; Melendez-Pena C; Parsons MS; Migueles SA; Connors M; Miconiatis S; Song R; Boulet S; Bruneau J; Tremblay CL; Bernard NF;
Clin Immunol; 2012 Jun; 143(3):246-55. PubMed ID: 22445844
[TBL] [Abstract][Full Text] [Related]
11. Genetic profiles of killer-cell immunoglobulin-like receptors and HLA ligands in Thai blood donors.
Kitpoka P; Tammakorn C; Chaisri S; Leelayuwat C; Mongkolsuk T; Thammanichanond D
Hum Immunol; 2016 Jun; 77(6):470-5. PubMed ID: 27131859
[TBL] [Abstract][Full Text] [Related]
12. [Receptor-ligand analysis of killer cell Ig-like receptor in Jiangsu Han population].
Jiang LX; Xu LH; Qi CP; Wang YF
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):863-5. PubMed ID: 22863597
[TBL] [Abstract][Full Text] [Related]
13. Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.
Ying H; Xu J; Zhang X; Liang T; Bai X
EBioMedicine; 2022 May; 79():103987. PubMed ID: 35439678
[TBL] [Abstract][Full Text] [Related]
14. The Importance of HHLA2 in Solid Tumors-A Review of the Literature.
Kula A; Koszewska D; Kot A; Dawidowicz M; Mielcarska S; Waniczek D; Świętochowska E
Cells; 2024 May; 13(10):. PubMed ID: 38786018
[TBL] [Abstract][Full Text] [Related]
15. Conservation, Extensive Heterozygosity, and Convergence of Signaling Potential All Indicate a Critical Role for KIR3DL3 in Higher Primates.
Leaton LA; Shortt J; Kichula KM; Tao S; Nemat-Gorgani N; Mentzer AJ; Oppenheimer SJ; Deng Z; Hollenbach JA; Gignoux CR; Guethlein LA; Parham P; Carrington M; Norman PJ
Front Immunol; 2019; 10():24. PubMed ID: 30745901
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation.
Bastos-Oreiro M; Anguita J; Martínez-Laperche C; Fernández L; Buces E; Navarro A; Pascual C; Pérez-Corral A; Balsalobre P; Muñoz C; Kwon M; Serrano D; Perez-Martinez A; Buño I; Gayoso J; Díez-Martín JL
Eur J Haematol; 2016 May; 96(5):483-91. PubMed ID: 26133015
[TBL] [Abstract][Full Text] [Related]
17. NK Cell Education in Tumor Immune Surveillance: DNAM-1/KIR Receptor Ratios as Predictive Biomarkers for Solid Tumor Outcome.
Guillamón CF; Martínez-Sánchez MV; Gimeno L; Mrowiec A; Martínez-García J; Server-Pastor G; Martínez-Escribano J; Torroba A; Ferri B; Abellán D; Campillo JA; Legaz I; López-Álvarez MR; Moya-Quiles MR; Muro M; Minguela A
Cancer Immunol Res; 2018 Dec; 6(12):1537-1547. PubMed ID: 30242020
[TBL] [Abstract][Full Text] [Related]
18. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
19. Certain Killer Immunoglobulin-Like Receptor (KIR)/KIR HLA Class I Ligand Genotypes Influence Natural Killer Antitumor Activity in Myelogenous Leukemia but Not in Acute Lymphoblastic Leukemia: A Case Control Leukemia Association Study.
Varbanova VP; Mihailova S; Naumova E; Mihaylova AP
Turk J Haematol; 2019 Nov; 36(4):238-246. PubMed ID: 31337191
[TBL] [Abstract][Full Text] [Related]
20. KIR-HLA interactions extend human CD8+ T cell lifespan in vivo.
Zhang Y; Yan AW; Boelen L; Hadcocks L; Salam A; Gispert DP; Spanos L; Bitria LM; Nemat-Gorgani N; Traherne JA; Roberts C; Koftori D; Taylor GP; Forton D; Norman PJ; Marsh SG; Busch R; Macallan DC; Asquith B
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37071474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
